Oncimmune Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Oncimmune Holdings wird ein Gewinn- und Umsatzwachstum von 100.9% bzw. 105.1% pro Jahr prognostiziert, während der Gewinn pro Aktie um 32% pro Jahr wachsen soll.

Wichtige Informationen

100.9%

Wachstumsrate der Gewinne

32.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	37.3%
Wachstumsrate der Einnahmen	105.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	21 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Estimating The Intrinsic Value Of Oncimmune Holdings plc (LON:ONC)

Aug 16

Gewinn- und Umsatzwachstumsprognosen

AIM:ONC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (GBP Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
8/31/2025	7	0	-1	-1	1
8/31/2024	3	-3	-4	-3	1
2/29/2024	1	-3	-6	-5	N/A
11/30/2023	1	-5	-6	-6	N/A
8/31/2023	1	-6	-7	-7	N/A
8/31/2022	2	-5	-6	-5	N/A
5/31/2022	3	-10	-7	-6	N/A
2/28/2022	4	-8	-7	-6	N/A
11/30/2021	3	-7	-7	-5	N/A
8/31/2021	4	-6	-6	-5	N/A
5/31/2021	4	-5	-6	-5	N/A
2/28/2021	3	-5	-6	-6	N/A
11/30/2020	2	-6	-7	-7	N/A
8/31/2020	1	-7	-8	-8	N/A
5/31/2020	1	-8	-9	-9	N/A
2/29/2020	0	-9	-9	-9	N/A
11/30/2019	0	-9	-9	-9	N/A
8/31/2019	0	-9	-8	-8	N/A
5/31/2019	0	-8	-8	-7	N/A
2/28/2019	0	-8	-7	-7	N/A
11/30/2018	0	-7	-7	-7	N/A
8/31/2018	0	-7	-7	-6	N/A
5/31/2018	0	-6	-6	-6	N/A
2/28/2018	0	-6	-6	-6	N/A
11/30/2017	0	-5	N/A	-5	N/A
8/31/2017	0	-5	N/A	-5	N/A
5/31/2017	0	-5	N/A	-4	N/A
2/28/2017	0	-8	N/A	-4	N/A
11/30/2016	0	-10	N/A	-5	N/A
8/31/2016	0	-9	N/A	-4	N/A
5/31/2016	0	-8	N/A	-3	N/A
5/31/2015	1	-2	N/A	-2	N/A
5/31/2014	1	-1	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ONC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ONC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ONC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ONCDie Einnahmen des Unternehmens (105.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt UK (3.6% pro Jahr).

Hohe Wachstumseinnahmen: ONCDie Einnahmen des Unternehmens (105.1% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ONC in 3 Jahren voraussichtlich hoch sein wird

Oncimmune Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

No longer forecast to breakeven

Oncimmune Holdings plc Reaffirms Revenue Guidance for the Fiscal Year 2024 and Provides Earnings Guidance for the Fiscal Year 2025

Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024

Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024

Price target increased to UK£2.22

Recent updates

New major risk - Shareholder dilution

No longer forecast to breakeven

New major risk - Financial data availability

Oncimmune Holdings plc Reaffirms Revenue Guidance for the Fiscal Year 2024 and Provides Earnings Guidance for the Fiscal Year 2025

New major risk - Negative shareholders equity

New major risk - Share price stability

Oncimmune Holdings plc to Report First Half, 2024 Results on May 21, 2024

Less than half of directors are independent

Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024

Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: UK£0.085 loss per share (vs UK£0.13 loss in FY 2022)

New major risk - Share price stability

Oncimmune Holdings plc, Annual General Meeting, Feb 26, 2024

New minor risk - Financial data availability

Oncimmune Holdings plc Announces Board Changes

Less than half of directors are independent

Oncimmune Holdings plc Announces Changes to the Board

Oncimmune Holdings plc Announces Executive Changes

Freenome Holdings, Inc. acquired Oncimmune Limited and Oncimmune Europe GmbH from Oncimmune Holdings plc (AIM:ONC) for £13 million.

Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2023

Oncimmune Holdings plc Announces Appointment of John Goold as Non-Executive Director

Oncimmune Holdings plc has completed a Follow-on Equity Offering in the amount of £2.1 million.

Less than half of directors are independent

Full year 2022 earnings released: UK£0.14 loss per share (vs UK£0.072 loss in FY 2021)

Estimating The Intrinsic Value Of Oncimmune Holdings plc (LON:ONC)

Oncimmune Holdings plc Announces Board Changes

Price target increased to UK£2.22

Less than half of directors are independent

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Oncimmune Holdings Ordinary Shares to Be Deleted from Other OTC

Oncimmune Holdings plc Announces EarlyCDT Lung Test Approved by Ministry of Health for Aragon, Spain

Full year 2021 earnings released: UK£0.072 loss per share (vs UK£0.13 loss in FY 2020)

Oncimmune Holdings plc Announces the Pre-Publication of the First Results from Its Collaboration with Cedars-Sinai Medical Center in Los Angeles

Oncimmune Holdings plc Presents Clinical Abstracts on Melflufen At the 2021 American Society of Clinical Oncology

Oncopeptides AB (publ) Presents New Clinical and Preclinical Melflufen Data At the Upcoming European Hematology Association Meeting

New 90-day high: UK£1.94

First half 2021 earnings released: UK£0.041 loss per share (vs UK£0.083 loss in 1H 2020)

Oncimmune Holdings plc to Report First Half, 2021 Results on Feb 15, 2021

Oncimmune Holdings plc Announces Steps Down of Cheung to as a Non-Executive Director, Effective 19 January 2021

New 90-day high: UK£1.90

Oncimmune Holdings plc Signs Commercial Contracts

Oncimmune Holdings plc, Annual General Meeting, Nov 30, 2020

Annual earnings released: Earnings beat expectations, revenue disappoints

Full year earnings released - UK£0.13 loss per share

Oncimmune Holdings plc to Report Fiscal Year 2020 Results on Oct 30, 2020

New 90-day high: UK£1.73

Oncimmune Holdings plc Initiates U.S. Expanded Access Program with Melflufen in Triple-Class Refractory Multiple Myeloma

Oncimmune Holdings plc announced that it has received £5.25 million in funding from Balderton Capital (UK) LLP and other investors

Oncimmune Holdings plc Signs Collaboration with Genentech

New 90-day high - UK£1.51

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken